Specific Biologics raises $35 million for ALS gene editing

By Olivia Hart

What did the $35 million Series A fund?

Specific Biologics said it completed an oversubscribed $35 million Series A led by Hatteras Venture Partners, moving its precision gene-editing ALS program toward initial human evaluation.

Under the announced structure, existing investors Lumira Ventures and adMare BioInnovations participated alongside new investors Genesys Capital, BDC’s Life Sciences Venture Fund, DeepWork Capital, and Seido Capital. Specific Biologics said the financing supports clinical development of its lead candidate, which uses its proprietary Dualase gene-editing technology.

The announcement disclosed no valuation, ownership percentages or investment sizes. Specific Biologics said the financing brought together a broader group of life-sciences investors with experience supporting biotechnology companies through clinical development.

Takeaway: The financing supplies clinical capital and a wider investor syndicate, but the deal’s economics remain undisclosed.

What will the first clinical test establish?

Specific Biologics said its lead candidate initially targets amyotrophic lateral sclerosis associated with mutations in the C9ORF72 gene. The company plans to advance it through early clinical biomarker proof-of-concept in the first patient cohort of an adaptive Phase I/II clinical trial.

Brent Stead, CEO of Specific Biologics, said:

“This financing represents a defining step toward our goal of bringing a potentially transformative medicine to people living with ALS. Our goal is to address the disease at its genetic source to create a new therapeutic option for patients who have waited far too long.”

Stead described the financing as a step toward a new treatment option, not evidence that one exists. Specific Biologics said the program remains investigational and that its safety and effectiveness have not been established in patients.

Takeaway: The first cohort must generate a biomarker signal before the company can support Stead’s larger claim of addressing ALS at its genetic source.

How does Dualase work, and what can it target?

According to Specific Biologics, Dualase is designed to remove abnormal DNA repeat expansions while preserving normal genetic sequences needed for biological function. The company said it has demonstrated gene-editing activity in preclinical studies involving multiple neuromuscular repeat-expansion conditions.

Specific Biologics said abnormal repeat expansions are associated with more than 40 genetic disorders, creating potential applications beyond the initial ALS program. That association does not mean the company has demonstrated treatments for all 40 conditions; the broader use cases remain potential rather than clinically validated indications.

The company said it hopes its approach can address certain genetic causes of disease directly rather than focusing exclusively on managing symptoms. The financing gives it resources to move the technology from preclinical development toward initial human clinical evaluation, but it does not supply clinical efficacy data.

Takeaway: Dualase has preclinical support and a wide disease rationale, but its value still depends on translating laboratory activity into safe human results.

What is driving investor conviction?

Ben Scruggs, partner at Hatteras Venture Partners, said:

“Gene editing has the potential to transform the treatment of genetic diseases, but realizing that promise requires overcoming longstanding challenges in precision, specificity and delivery. Specific Biologics has developed a highly differentiated technology with significant therapeutic and commercial potential designed to address these challenges, supported by compelling preclinical evidence.”

Scruggs cited technological differentiation and preclinical evidence, but the announcement provided no patient outcomes or comparative clinical data. His commercial-potential assessment remains an investor judgment rather than a demonstrated market result.

Nikhil Thatte, partner at Lumira Ventures, said:

“Our decision to invest meaningful additional capital in Specific reflects our growing conviction in the scientific differentiation, clinical potential and long-term value of the Dualase platform. We believe the opportunity to generate early clinical proof-of-concept in ALS patients represents an important inflection point for the company and a meaningful step toward realizing the broader promise of its technology.”

Thatte identified the first ALS cohort as the point where investors will seek evidence for the platform. His statement confirms that Lumira added capital, although the announcement did not disclose the size of that investment.

Takeaway: Investors are underwriting a first clinical test and a wider platform story, not an already validated ALS treatment.

What must happen next?

The immediate milestone is early clinical biomarker proof-of-concept in the first patient cohort of the adaptive Phase I/II trial. Specific Biologics will need to show that Dualase can produce its intended biological effect in people carrying C9ORF72 mutations.

Even if the first cohort produces the intended biomarker signal, the company would still need human evidence of safety and effectiveness. The more than 40-disorder opportunity would also remain largely dependent on preclinical work and subsequent clinical testing.

Takeaway: The next checkpoint is biomarker proof-of-concept in the first patient cohort; safety and effectiveness remain unproven in patients.